December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.88 +0.36 (+1.92%)
Delayed Quote Updated: 10:10 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
News headline image
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer ↗
 
Via Benzinga
News headline image
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
News headline image
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
7 Stocks Under $15 to Buy and Hold Forever ↗
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul. 
Via InvestorPlace
News headline image
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate ↗
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of... 
Via Benzinga
News headline image
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗
 
Via Benzinga
News headline image
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26 ↗
CNBC The Aviation Sector Is Slammed By Sky-High Rents 
Via Benzinga
News headline image
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact ↗
 
Via Benzinga
News headline image
Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried ↗
Shares hit their lowest point since November on the FDA's decision in HAE. 
Via Investor's Business Daily
News headline image
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Peering Into Takeda Pharmaceutical's Recent Short Interest ↗
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold... 
Via Benzinga
News headline image
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets ↗
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
Via Benzinga
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... 
Via FinancialNewsMedia
News headline image
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents ↗
 
Via Benzinga
News headline image
Peering Into Takeda Pharmaceutical's Recent Short Interest ↗
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which... 
Via Benzinga
News headline image
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful ↗
 
Via Benzinga
News headline image
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Looking Into Takeda Pharmaceutical's Recent Short Interest ↗
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which... 
Via Benzinga
News headline image
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. 
Via Benzinga
News headline image
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.